Korean J Lab Med.  2007 Oct;27(5):355-359. 10.3343/kjlm.2007.27.5.355.

Comparison Study with Enzyme Immunoassay and Chemiluminescence Immunoassay for Hepatitis B Virus Surface Antigen Detection

• Huh HJ
• Chae SL
• Cha YJ

• KMID: 1781535
• DOI: http://doi.org/10.3343/kjlm.2007.27.5.355

Abstract

BACKGROUND: The serological detection of the surface antigen (HBsAg) of hepatitis B virus (HBV) is the basis of detection of HBV infections in blood donors and patients with hepatitis. The aim of this study was to compare the performance of HBsAg enzyme-linked immunosorbent assay (ELISA) and HBsAg chemiluminescence immunoassay used in Korea. METHODS: We compared seven assays: Architect i 2000 (Abbott Laboratories, USA), Elecsys 2010 immunoanalyzer (Roche Diagnostics, Germany), Advia Centaur (Bayer Healthcare, USA), Murex HBsAg version 3 (Abbott Laboratories, USA), Enzygnost HBsAg 5.0 (DADE Behring, Germany), LG HBsAg ELISA (LG, Korea), and Genedia HBsAg ELISA 3.0 (Greencross Medical Science, Korea). We evaluated the sensitivity of each assay by testing serially diluted WHO HBsAg reference material, two seroconversion panels, and recombinant HBsAg with three mutations in the 'a' determinant. RESULTS: The lowest HBsAg level detected by each assay using WHO reference material was variable from 0.05 (Murex and Advia) to 0.2 IU/mL. When testing 21 seroconversion panels, the total number of positive samples was 15 by Murex and 14 by Architect. Murex, LG, and Architect detected all of the 3 mutant samples tested. CONCLUSIONS: Analytical sensitivity and mutant detecting ability among HBsAg commercial assays were variable and not related to the analytical methods, but related to the manufacturer's reagents. We suggest that each laboratory should select an HBsAg assay based on analytical performance, test throughput, and the applicability of full automation.

Keyword

Hepatitis B surface antigens; Chemiluminescence immunoassay; Enzyme-linked immunosorbent assay

MeSH Terms

Chemiluminescent Measurements/*methods
Enzyme-Linked Immunosorbent Assay/*methods
Hepatitis B Surface Antigens/*blood
Humans
Reagent Kits, Diagnostic
Reference Values
Sensitivity and Specificity

Reference

1.Lee DH., Kim JH., Nam JJ., Kim HR., Shin HR. Epidemiological findings of hepatitis B infection based on 1998 National Health and Nutrition Survey in Korea. J Korean Med Sci. 2002. 17:457–62.

2.Kleinman SH., Kuhns MC., Todd DS., Glynn SA., McNamara A., Di-Marco A, et al. Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening. Transfusion. 2003. 43:696–704.

3.Jilg W., Sieger E., Zachoval R., Schatzl H. Individuals with antibodies against hepatitis B core antigen as the only serological marker for hepatitis B infection: high percentage of carriers of hepatitis B and C virus. J Hepatol. 1995. 23:14–20.

4.Coleman PF., Chen YC., Mushahwar IK. Immunoassay detection of hepatitis B surface antigen mutants. J Med Virol. 1999. 59:19–24.

5.Weber B., Dengler T., Berger A., Doerr HW., Rabenau H. Evaluation of two new automated assays for hepatitis B virus surface antigen (HBsAg) detection: IMMULITE HBsAg and IMMULITE 2000 HBsAg. J Clin Microbiol. 2003. 41:135–43.

6.Song BC., Kim SH., Kim H., Ying YH., Kim HJ., Kim YJ, et al. Prevalence of naturally occurring surface antigen variants of hepatitis B virus in Korean patients infected chronically. J Med Virol. 2005. 76:194–202.

7.Drosten C., Nippraschk T., Manegold C., Meisel H., Brixner V., Roth WK, et al. Prevalence of hepatitis B virus DNA in anti-HBc-positive/HBsAg-negative sera correlates with HCV but not HIV serostatus. J Clin Virol. 2004. 29:59–68.

8.Alhababi F., Sallam TA,Tong CY. The significance of ‘anti-HBc only’ in the clinical virology laboratory. J Clin Virol. 2003. 27:162–9.

9.Whang DH., Um TH. Comparison of immunochromatography assays and quantitative immunoassays for detecting HBsAg and Anti-HBs. Korean J Lab Med. 2005. 25:186–91. (황동희및엄태현. B형간염항원 및 항체 검사를 위한 신속검사법과 정량적 효소면역법의 비교. 대한진단검사의학회지 2005;25: 186-91.).

10.Yoo SJ., Oh HJ., Shin BM. Comparison of 3 automated immunoassays for Hepatitis B surface antigen. Korean J Lab Med. 2006. 26:282–6. (유수진, 오혜전, 신보문. B형간염표면항원 측정을 위한 세가지 자동화면역측정법의비교. 대한진단검사의학회지 2006;26: 282-6.).

11.Cha YJ., Yang JS., Chae SL. Evaluation of indigenously manufactured immunochromatographic assay systems for rapid detection of Hepatitis B surface antigen and antibody. Korean J Lab Med. 2006. 26:52–7. (차영주, 양주석, 채석래. 국내에서생산되는면역크로마토그래피법을이용한 B형간염표면항원및항체검사제품의평가. 대한진단검사의학회지 2006;26: 52-7.).

12.Fujii H., Moriyama K., Sakamoto N., Kondo T., Yasuda K., Hiraizumi Y, et al. Gly145 to Arg substitution in HBs antigen of immune escape mutant of hepatitis B virus. Biochem Biophys Res Commun. 1992. 184:1152–7.

13.Cha YJ. Detection of Hepatitis B virus surface antigen mutants. Korean J Lab Med. 2005. 25:442–7. (차영주. B형간염바이러스표면항원변이검출에관한연구. 대한진단검사의학회지 2005;25: 442-7.).

14.Song BC., Cui XJ., Kim H. Hepatitis B virus genotypes in Korea: an endemic area of hepatitis B virus infection. Intervirology. 2005. 48:133–7.

15.Kim H., Jee YM., Song BC., Shin JW., Yang SH., Mun HS, et al. Molecular epidemiology of hepatitis B virus (HBV) genotypes and serotypes in patients with chronic HBV infection in Korea. Intervirology. 2007. 50:52–7.

16.Bae SH., Yoon SK., Jang JW., Kim CW., Nam SW., Choi JY, et al. Hepatitis B virus genotype C prevails among chronic carriers of the virus in Korea. J Korean Med Sci. 2005. 20:816–20.

17.Hou J., Wang Z., Cheng J., Lin Y., Lau GK., Sun J, et al. Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers. Hepatology. 2001. 34:1027–34.

18.Ogura Y., Kurosaki M., Asahina Y., Enomoto N., Marumo F., Sato C. Prevalence and significance of naturally occurring mutations in the surface and polymerase genes of hepatitis B virus. J Infect Dis. 1999. 180:1444–51.

19.Weber B. Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact. J Clin Virol. 2005. 32:102–12.

20.Koyanagi T., Nakamuta M., Sakai H., Sugimoto R., Enjoji M., Koto K, et al. Analysis of HBs antigen negative variant of hepatitis B virus: unique substitutions, Glu129 to Asp and Gly145 to Ala in the surface antigen gene. Med Sci Monit. 2000. 6:1165–9.

21.Jeantet D., Chemin I., Mandrand B., Tran A., Zoulim F., Merle P, et al. Cloning and expression of surface antigens from occult chronic hepatitis B virus infections and their recognition by commercial detection assays. J Med Virol. 2004. 73:508–15.

22.Levicnik-Stezinar S. Hepatitis B surface antigen escape mutant in a first time blood donor potentially missed by a routine screening assay. Clin Lab. 2004. 50:49–51.

23.Moerman B., Moons V., Sommer H., Schmitt Y., Stetter M. Evaluation of sensitivity for wild type and mutant forms of hepatitis B surface antigen by four commercial HBsAg assays. Clin Lab. 2004. 50:159–62.